Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | recruiting | Phase 2 / Phase 3 | 29 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | recruiting | Phase 1 | 48 | Stanford UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06886321 |
| Prostate Irreversible Electroporation Study |
| recruiting |
| N/A |
| 10 |
| Chinese University of Hong KongOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07090109 | PITCH - Impacting Hereditary Cancer Testing | not yet recruiting | N/A | 200 | Rachel MillerOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07491198 | Effect Of Trendelenburg Position And Pneumoperitoneum On Optic Nerve Sheath Diameter In Robot-Assisted Prostatectomy(ONSD-RALP) | recruiting | — | 50 | Ege UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07502157 | Massage, Oncology, Pain, Anxiety, Feasibility(IMPACT) | recruiting | N/A | 24 | Jill ColeOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01480154 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02595892 | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | active not recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT04396808 | Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | active not recruiting | N/A | 805 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05804318 | Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer(ARTIA-Prostate) | recruiting | N/A | 132 | Varian, a Siemens Healthineers CompanyINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06607783 | PRostate Cancer Enhanced Diagnosis by Calibration Technology(PREDICT) | recruiting | — | 66 | Gold Standard PhantomsINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06834672 | Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 450 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
| NCT07226713 | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors(POSTPONE) | recruiting | Phase 2 | 32 | Medical College of WisconsinOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07468708 | The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) | recruiting | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07576335 | Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy(ROBOPREP) | recruiting | Phase 2 | 64 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China(RAINFOL-02) | recruiting | Phase 3 | 82 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVIV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery(NeoOVSV) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07797283 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1(MAESTRA 3) | not yet recruiting | Phase 3 | 590 | Incyte CorporationINDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07808528 | Advanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)(ASPIRE MS) | not yet recruiting | N/A | 660 | University College, LondonOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810660 | RE-irradiation for Isolated FOCal Recurrence of Prostate Cancer With Ultrahypofracted SBRT(RE-FOCUS) | not yet recruiting | — | 60 | European Institute of OncologyOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03035500 | Long-Term Follow-Up in Patients With Prostate Cancer After Surgery | active not recruiting | N/A | 2,500 | City of Hope Medical CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03354416 | Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer | recruiting | — | 10,000 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05800665 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Genentech, Inc.INDUSTRY | 7 | Sep 8, 2026 | clinicaltrials |
| NCT06067295 | Longitudinal Advanced Prostate Cancer Cohort (LAPCC) | recruiting | — | 300 | University of Southern CaliforniaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06690970 | Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients | recruiting | — | 500 | Tianjin Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer(ASpiRE) | recruiting | Phase 1 / Phase 2 | 78 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07041606 | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation(IREN) | recruiting | — | 500 | AstraZenecaINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07224009 | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | recruiting | Phase 2 | 60 | University of ArkansasOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer | recruiting | Phase 1 | 118 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE(SALVAGE) | not yet recruiting | Phase 2 | 62 | University of British ColumbiaOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials